US drug major Bristol Myers Squibb’s Sotyktu (deucravacitinib), a once-daily oral tablet, has been recommended for use on the National Health Service (NHS) in E 28 June 2023
Mounjaro (tirzepatide) has not been recommended in draft guidance issued by the National Institute for Health and Care Excellence (NICE) on Tuesday for treating 27 June 2023
Four companies in the Asia Pacific region have taken out licenses with The Medicines Patent Pool (MPP) to manufacture generic versions of Tasigna (nilotinib). 22 June 2023
The US drug industry is not happy with the Inflation Reduction Act (IRA) and is pursuing broad legal action in an attempt to limit its impact. 22 June 2023
Healthcare cost pressures have started easing in all but one of the seven major markets in 2023, as physicians noticed a decline in the number of patients postp 20 June 2023
Generics and biosimilar medicines company Sandoz has trumpeted the launch of what it calls a ‘global roadmap to increase patient access to biologic medicines’. 15 June 2023
The Biden administration has provided more evidence of its desire to follow rhetoric with action on lowering drug prices through the Inflation Reduction Act (IR 12 June 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.